Evidence-based Medicine in Oncology Practice

Challenges in Today’s Healthcare Environment

Medical Education Exchange (MEDX) will host a MEDX Regional Oncology CME/CPE/CNE Conference in Fall 2017 for the community-based oncology care team. Both clinical and topical content for the conference will focus on the fundamental principles of oncology care and will be created with the Oncology Care Model (OCM) and The Medicare Access and CHIP Reauthorization Act of 2015 Quality Payment Program (MACRA QPP) in mind. In addition to the live regional conference, MEDX will partner with Rockpointe Oncology on the development of the clinical content.

Why Attend MEDX Oncology Conferences?

The MEDX|Oncology Conference Chairman Gary I. Cohen, MD, Emeritus Director of the Sandra and Malcolm Berman Cancer Institute at Greater Baltimore Medical Center, and an expert panel of leading oncologists will discuss integration of evidence-based medicine and quality of care.

Nationally recognized expert panel includes:

Sanjiv S. Agarwala, MD

Professor & Chief, Hematology & Oncology
St Luke’s Cancer Center & Temple University
Bethlehem, PA

Al Benson, MD

Professor of Medicine-Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, IL

Joseph R. Bertino, MD

American Cancer Society Professor
Rutgers Cancer Institute of New Jersey
University Professor of Medicine & Pharmacology
Rutgers –Robert Wood Johnson Medical School
New Brunswick, NJ

Jennifer Billiet, MGC, CGC

Genetic Counselor
Greater Baltimore Medical Center
Harvey Institute for Human Genetics
Baltimore, MD

Gary I. Cohen, MD

Associate Professor, Oncology, Johns Hopkins
Director Emeritus, Berman Cancer Institute
Greater Baltimore Medical Center
Baltimore, MD

Saar Gill, MD, PhD

Assistant Professor of Medicine
Division of Hematology‐Oncology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Paul A. Hamlin, MD

Chief of Medical Oncology, MSKCC Basking Ridge
Associate Member Physician, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
Division of Hematologic Oncology
Associate Professor of Medicine
Weill Medical College of Cornell University Medical College
New York, NY

Benjamin Levy, MD

Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Washington, DC

Neal J. Meropol, MD

Vice President of Research Oncology
Flatiron Health
New York, NY

Therese Mulvey, MD

Medical Oncology
Massachusetts General Hospital
Boston, MA

Charles Saunders, MD

Chief Executive Officer
IntegraConnect
West Palm Beach, FL

Joseph Sparano, MD

Professor of Medicine & Women’s Health
Albert Einstein College of Medicine
Associate Chairman, Department of Oncology
Montefiore Medical Center
Bronx, NY

Mark N. Stein, MD

Medical Oncologist
Cancer Institute of New Jersey
New Brunswick, NJ

Our expert panel will update physicians on current evidence-based management of multiple tumor types, including breast, CLL, GU, GI, multiple myeloma, NHL, NSCLC, skin, and BRCA and familial associated cancers.

Participants will also examine the integration of value-based patient care through the Medicare Access and CHIP Reauthorization Act’s (MACRA) Oncology Care Model (OCM) payment model and explore real-life, practical experiences of clinicians who have implemented the model.

Learning Objectives

At the conclusion of this 2-day conference, participants should be able to demonstrate the ability to:

  • Incorporate treatment pathways and quality measures to ensure patients receive guideline-consistent care
  • Evaluate the sequential and combination administration of chemotherapy and targeted agents to optimize patient survival
  • Discuss current recommendations for diagnostic testing across multiple tumor types to facilitate treatment selection
  • Assess the safety and efficacy of currently approved and emerging agents for primary and subsequent management of multiple tumor types with attention to cost/benefit and toxicity considerations
  • Evaluate communication strategies and resources to increase patient access and engagement

On July 1, 2016, the Center for Medicare & Medicaid Innovation launched the OCM within 195 oncology clinics across the US. The Oncology Care Model (OCM) is a new payment and delivery model designed to improve the effectiveness and efficiency of oncology care and aims to provide higher quality, better coordinated oncology care. Under this multi-payer model physician practices enter into payment arrangements that provide financial incentives based on performance accountability for episodes of care surrounding chemotherapy administration to cancer patients. The practices participating in OCM have committed to providing enhanced services to Medicare beneficiaries such as care coordination, navigation, and integration of evidence-based care and national treatment guidelines.

Despite including Medicare Fee-For-Service, the Oncology Care Model is facilitating the transition to value-based care accountability as the standard in oncology care. For those oncology clinics not included in the 195 clinics piloting the OCM, the focus on value and quality continue with payment models and requirements under MACRA.

We believe that education is the key to a transition to value-based care and recognize the need for a quality improvement event that responds to this new frontier in oncology care. MEDX is committed to delivering high-quality, evidence-based clinical education within the context of a dynamic reimbursement and healthcare environment. Our mission is to improve oncology patient experience through practical, quality-focused, clinical education – education designed to empower clinicians, strengthen the provider/patient relationship, and help providers understand and effectively respond to the changes in the healthcare industry.

MEDX Oncology is a series of regional CME conferences designed for the oncology care team. These conferences will provide clinical updates to treatment teams within the context of emerging payment models and meeting reporting requirements in terms of evidence-based care, adherence to clinical guidelines, quality measures, and how to optimally integrate new data and novel agents into practice.

Each MEDX Oncology Conference is designed to:

Inform oncology care teams about the transition from Fee-For-Service to the value-based Oncology Care Model

Educate oncology care teams on emerging therapies and how to apply treatment pathways in complex, high-risk patient populations

Share best practices to improve patient/caregiver experience and reduce patient centered barriers to care

MEDX Regional Conferences improve the learning process by utilizing the ARRAY™ tablet system, an innovative technology designed to deliver content; collect, manage, and analyze data; and engage participants – ultimately leading to increased knowledge retention and better decision making.

ARRAY brings interactivity with clinical content into the hands of each conference attendee. Using their own laptop or tablet, or on an iPad provided by MEDX, participants utilize ARRAY to view resources, participate in case studies, answer polling questions, view and interact with the educational content, submit questions to the faculty, and evaluate each session.

With ARRAY, each topic presented at a MEDX Regional Conference culminates in thorough analytics using multiple criteria and measurement techniques. Analytics are designed to accurately assess participant engagement, changes in participant knowledge, competence, and performance, while helping to identify needs, gaps, and barriers that can be addressed in future CME activities.

MEDX ONCOLOGY 2017 CONFERENCE LOCATIONS

Conference Agenda

Day One

7:00am – 7:45am
Registration and Continental Breakfast

7:45am – 8:00am
Welcome and Introduction and iPad Instruction

8:00am – 9:30am
Payment Models and Practice Changes: Meeting requirements of OCM & MACRA

9:30am – 10:45am
Navigating New Options to Improve Outcomes in Multiple Myeloma

10:45am – 11:00am
Break

11:00am – 12:15pm
Targeted Therapy for Skin Malignancies: Basal Cell Carcinoma, Melanoma, and Merkel Cell

12:30pm – 1:45pm
Lunch Break

1:45pm – 2:30pm
Precision Medicine and Impact of Therapeutic Drug Levels

2:30pm – 3:30pm
Targeting EGFR, T790M, ALK, and ROS1 in NSCLC

3:30pm – 3:45pm
Break

3:45pm – 5:00pm
Metastatic Breast Cancer

Day Two

7:00am – 7:45am
Registration and Continental Breakfast

7:45am – 8:00am
Welcome and Introduction and iPad Instruction

8:00am – 9:00am
Integrating Immunotherapy for NSCLC

9:00am – 10:00am
Redefining Care for BRCA and Other Familial Associated Cancer Syndromes

10:00am – 10:15am
Break

10:15am – 11:30am
Achieving Precision Care in Gastrointestinal Cancers

11:30am – 12:30pm
Evidence-based Updates in Non-Hodgkin’s Lymphoma

12:30pm – 2:00pm
Lunch Break

2:00pm – 3:15pm
Patient-Centered Care for Genitourinary Cancers

3:15pm – 3:30pm
Break

3:30pm – 4:30pm
Treatment Strategies in Chronic Leukemias and Introduction to CAR-T Therapies

4:30pm – 5:00pm
Use of Oncology Quality Measures, Where do we go from here?

Promote your latest products, technologies, resources, programs, or services to hard-to-reach practicing health care clinicians.

Jointly provided by

Potomac Center for Medical Education (PCME), Postgraduate Institute for Medicine, and Rockpointe Oncology